AA
AMRX icon

ALPS Advisors’s Amneal Pharmaceuticals AMRX Stock Holding History

ALPS Advisors’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-50,325
Closed -$258K – 911
2021
Q2 		$258K Hold
50,325
– – ﹤0.01% 882
2021
Q1 		$339K Buy
+50,325
New +$279K ﹤0.01% 654

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ALPS Advisors's AMRX Position: Q3 2021 in Review

ALPS Advisors sold out of Amneal Pharmaceuticals (AMRX) in Q3 2021, closing a stake of 50,325 shares — an estimated $258K sold.

ALPS Advisors first reported a position in AMRX in Q1 2021 and held it in 2 quarters. The position peaked at $339K in Q1 2021. 154 funds tracked by Wall St. Rank hold AMRX as of Q3 2021.

  • ALPS Advisors reported no remaining Amneal Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • ALPS Advisors sold 50,325 Amneal Pharmaceuticals shares in Q3 2021, an estimated $258K.
  • ALPS Advisors first reported a position in Amneal Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • ALPS Advisors's Amneal Pharmaceuticals position peaked at $339K in Q1 2021.
  • 154 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2021.

Based on ALPS Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.